Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19
- Conditions
- COVID-19
- Interventions
- Device: Viruxal Oral and Nasal SprayOther: Placebo
- Registration Number
- NCT04357990
- Lead Sponsor
- Kerecis Ltd.
- Brief Summary
Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf (the "Device"). A double blind clinical trial will be conducted to evaluate the Device against placebo in COVID-19 positive, symptomatic patients in Iceland. Immediate access to COVID-19 patients is available through a well-organized COVID-19 outpatient follow-up clinic. Up to 128 patients with mild to moderate symptoms of COVID-19 will be recruited (so called "higher end of the low risk group"). These patients will be positive for COVID-19, be symptomatic with upper respiratory symptoms, but without involvement of the entire respiratory system. The patients will be randomized to receive treatment with the Study Device or to receive placebo. 64 patients will be randomized into the Study Device group and 64 patients into the Control group. Patients will administer Study Device or Control for 14 days and will have their symptoms recorded until no further symptoms are reported, up to a maximum of 28 days follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 128
- ≥18 years of age
- Positive for SARS-CoV-2 infection
- Has symptoms of upper respiratory infection
- Willing to participate in the clinical trial and gives consent
- Is not pregnant, nor actively trying to conceive a child.
- Under 18 years of age
- Negative for SARS-CoV-2 infection
- Severe symptoms of infection
- Symptoms involving the entire respiratory system, including Pneumonia
- Requires hospitalisation prior to study start
- Asymptomatic
- Pregnant or actively trying to conceive a child
- Other comorbidities that would prevent administration of the device
- Requirement to take regular medications administered by inhalation, or via the naso- and oropharyngeal route
- Patients with known allergies to Neem or Hypericum oil
- Patients with asthma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Viruxal Oral and Nasal Spray Viruxal Oral and Nasal Spray The Device will be administered to the oral and nasal passages, three times per day. Placebo Placebo The placebo will be administered to the oral and nasal passages, three times per day.
- Primary Outcome Measures
Name Time Method Number of days until complete resolution of symptoms per group 28 days The number of days until participants report no symptoms, which they attribute to COVID-19, will be compared between groups. Symptoms include: Fever (38.0°C or higher), chills, dry cough, cough with rise, shortness of breath (rest), shortness of breath (Exercise), dyspnoea, sore throat, runny nose, headache, myalgia/bone pain, anorexia, nausea, vomiting, loss of smell, osteoporosis, abdominal pain, diarrhea, weakness.
Number of hospital admissions per group 28 days The number of participants admitted to hospital due to deterioration of their condition due to COVID-19 will be compared between groups.
- Secondary Outcome Measures
Name Time Method Number of days until a reduction in symptoms per group 28 days The number of days until participants report a reduction in symptoms, which they attribute to COVID-19, will be compared between groups.
Symptoms include: Fever (38.0°C or higher), chills, dry cough, cough with rise, shortness of breath (rest), shortness of breath (Exercise), dyspnoea, sore throat, runny nose, headache, myalgia/bone pain, anorexia, nausea, vomiting, loss of smell, osteoporosis, abdominal pain, diarrhea, weakness.Number of adverse events per group 28 days The number of adverse events reported will be compared between groups.
Trial Locations
- Locations (1)
National Hospital of Iceland (Landspítali)
🇮🇸Reykjavík, Iceland